Evidence map›Paper›PMID 42719332›Full record

ArticleJournal of ginseng research2026

Structural characterization of a novel low-molecular-weight β-fructan from

Jinqian Yu, Chuangchuang Wang, Min Jiang, Tao Li, Yingjian Guo, Kai Zhong, Lei Zhao, Xiao Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of ginseng research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jinqian YuShandong Analysis and Test Center, Qilu University of Technology (Shandong Academy of Sciences), Jinan, 250014, China.
Chuangchuang WangShandong Analysis and Test Center, Qilu University of Technology (Shandong Academy of Sciences), Jinan, 250014, China.
Min JiangSchool of Pharmaceutical Sciences, Shandong University of Traditional Chinese Medicine, Jinan, 250355, China.
Tao LiShandong Analysis and Test Center, Qilu University of Technology (Shandong Academy of Sciences), Jinan, 250014, China.
Yingjian GuoShandong Analysis and Test Center, Qilu University of Technology (Shandong Academy of Sciences), Jinan, 250014, China.
Kai ZhongShandong Analysis and Test Center, Qilu University of Technology (Shandong Academy of Sciences), Jinan, 250014, China.
Lei ZhaoChemical Technology Research Institute of Shandong, Qingdao University of Science and Technology, Jinan, 250014, China.
Xiao WangShandong Analysis and Test Center, Qilu University of Technology (Shandong Academy of Sciences), Jinan, 250014, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Hyperuricemia (HUA), a widespread metabolic disorder, is closely associated with renal injury, tubulointerstitial fibrosis, and uric acid nephrolithiasis, posing a significant global health burden. In this study, we investigated the anti-hyperuricemic effects and underlying mechanisms of a novel low-molecular-weight β-fructan (AGP-W) derived from Methods: AGP-W was extracted from Results: AGP-W was characterized as a novel low-molecular-weight β-fructan. AGP-W administration significantly and dose-dependently reduced serum uric acid, creatinine, and blood urea nitrogen levels (P < 0.01), while ameliorating lipid metabolic disorders against the hyperuricemic mouse model. Mechanistically, AGP-W restored the expression of renal urate exporters ABCG2, OAT1/3, and OCT and suppressed the expression of URAT1, GLUT9. As for its effects on the intestines, it restored intestinal barrier integrity by upregulating tight junction proteins of ZO-1, Occludin, Claudin-1, reduced villus atrophy, and modulated gut microbiota by enriching Conclusion: AGP-W exerts potent anti-hyperuricemic effects by modulating renal urate transporters, and restoring intestinal barrier function with gut microbiota regulation. These findings highlight AGP-W as a promising natural candidate for hyperuricemia treatment.

Indexed as

Gut microbiotaHyperuricemiaLow-molecular-weight β-fructanPanax quinquefoliusUltra-high pressure-assisted extraction

Identifiers

PMID42719332
PMCPMC13554442

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.